{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:15:03Z","timestamp":1785802503173,"version":"3.56.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The vancomycin loading dose (LD) of 25 to 30 mg\/kg is a frequently practiced strategy to achieve effective concentrations from the first-treatment dose. However, considering only the body weight for dosing might be inadequate in critically ill patients due to pharmacokinetics changes. We sought to assess achieving optimal trough serum levels of vancomycin and AUC\n            <jats:sub>0\u201324<\/jats:sub>\n            \/MIC in the first 24 h of treatment by using an LD based on population pharmacokinetic parameters of critically ill patients. We performed a concurrent cohort study over 22 months of patients with severe sepsis who received intravenous vancomycin. The patients were treated with three different strategies to initiate vancomycin: without an LD (group A), with an LD of 25 to 30 mg\/kg (group B), and with an LD based on population pharmacokinetic parameters of the critically ill patient (group C). An optimal trough serum concentration was achieved in 5, 9, and 83% of patients in groups A, B, and C, respectively. The number of patients that reached optimal AUC\n            <jats:sub>0\u201324<\/jats:sub>\n            was 2 of 18 (11%), 5 of 11 (46%), and 11 of 12 (92%) in groups A, B, and C, respectively. The statistical analysis for both parameters revealed significant differences in group C with respect to other groups. The administration of the LD calculated from population pharmacokinetic parameters from the beginning of therapy is a more efficient strategy to obtain adequate trough serum concentrations and AUC\n            <jats:sub>0\u201324<\/jats:sub>\n            \/MIC in critical patients.\n          <\/jats:p>","DOI":"10.1128\/aac.00280-17","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:30:23Z","timestamp":1497313823000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients"],"prefix":"10.1128","volume":"61","author":[{"given":"Osvaldo","family":"\u00c1lvarez","sequence":"first","affiliation":[{"name":"Intensive Care Unit, Hospital del Salvador, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Cristian","family":"Plaza-Plaza","sequence":"additional","affiliation":[{"name":"Faculty of Chemistry, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Hospital del Salvador, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Peralta","sequence":"additional","affiliation":[{"name":"Rheumatology Laboratory, Hospital del Salvador, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristi\u00e1n A.","family":"Amador","sequence":"additional","affiliation":[{"name":"Laboratory of Renal Physiopathology, Center of Biomedical Research, Universidad Aut\u00f3noma de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Amador","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Hospital del Salvador, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021333"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318250aa72"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000330"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/491712"},{"key":"e_1_3_1_7_2","volume-title":"Program and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Ebert S","year":"1987","unstructured":"Ebert S LeggettJVogelmanB. 1987. In vivo cidal activity and pharmacokinetics parameters (PKPs) for vancomycin against methicillin-susceptible (MSSA) and -resistant (MRSA) S. aureus, abstr 439. InProgram and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology,Washington, DC."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00005"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0599-4"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70036-2"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir124"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01485-12"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.05.008"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4409-751"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/600884"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181961bff"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-006-0470-5"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015571163"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02459.x"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.08.017"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2013.01.004"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013510395"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.11.009"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/375057"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/acem.12934"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P634"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12036"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q195"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611040-00001"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199001000-00006"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-9-674"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.3.391"},{"key":"e_1_3_1_35_2","first-page":"178","volume-title":"Basic pharmacokinetics and pharmacodynamics: an integrated textbook and computer simulations","author":"Rosenbaum S","year":"2017","unstructured":"Rosenbaum S . 2017. Pharmacokinetics of an intravenous bolus injection in a two-compartment model, p 178\u2013197. InRosenbaumS (ed), Basic pharmacokinetics and pharmacodynamics: an integrated textbook and computer simulations,2nd ed,vol 1. John Wiley & Sons,Princeton, NJ.","edition":"2"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0213-005X(08)72695-8"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir935"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00280-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00280-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:03:49Z","timestamp":1645477429000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00280-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1128\/AAC.00280-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00280-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"2017-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00280-17"}}